Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2016

View Archived Issues

Yisheng completes phase I trial of PIKA hepatitis B vaccine

Taisho Pharmaceutical's TP-0463518 in clinical development for renal anemia

CRISPR/Cas9 gene editing advances, first patient receives cells with edited genes

Oral, ultra-long-acting form of ivermectin achieves sustained therapeutic serum drug concentrations

Chiesi Farmaceutici acquires Atopix Therapeutics

Karolinska Development company raises funds to advance development of GR-3027

Eli Lilly Japan and Torii Pharmaceutical launch Taltz in Japan

BioLineRx inlicenses project for dry eye syndrome

KalVista Pharmaceuticals closes merger with Carbylan

Immunovaccine's DPX-Survivac wins EMA orphan drug designation

ENDURANCE-4 trial shows efficacy of glecaprevir/pibrentasvir in HCV genotypes 4-6

Ability Pharmaceuticals begins phase II study of ABTL-0812

FDA issues complete response letter for Green Cross's IVIG-SN

Enamine and Pcovery extend collaboration

Phase III trial of mepolizumab for eosinophilic granulomatosis with polyangiitis meets endpoints

Gates Foundation grant supports NovoBiotic's work on orally active analogues of teixobactin for TB

Cancer candidate PRI-724 shows antifibrotic potential in patients with HCV and cirrhosis

Farnesoid X receptor agonist LJN-452 well tolerated in first-in-human study

Acorda ends development of dalfampridine to improve post-stroke walking difficulties

FDA grants orphan drug designation to PQR-309

Primary endpoint not met in phase III study of solanezumab for mild dementia due to Alzheimer's

Ruga Corporation changes name to Aravive Biologics

Rgenix patents SLC6A8 inhibitors for cancer

University of Colorado patent reveals beta-lactam antibiotic sensitizers

AstraZeneca describes LTC4 synthase inhibitors

Chiesi Farmaceutici reports compounds for asthma and COPD

Bayer Healthcare divulges TNKS1/TNKS2 inhibitors for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...